Advertisement


Nirav N. Shah, MD, on DLBCL: New Data on Split-Dose R-CHOP for Older Patients

2023 ASCO Annual Meeting

Advertisement

Nirav N. Shah, MD, of the Medical College of Wisconsin, discusses phase II results showing that split-dose R-CHOP offers older patients with diffuse large B-cell lymphoma (DLBCL) an equivalent dose intensity as R-CHOP-21 through a fractionated dosing schedule, improving tolerability. At the end of treatment for these older patients, a complete response rate of 71% was comparable to outcomes with R-CHOP in younger patients with the disease (Abstract 7554).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The optimal management of older patients with DLBCL remains unclear and is very variable from practice to practice. The most commonly used regimen for older patients with diffuse large B-cell lymphoma is a regimen called R-mini-CHOP, which is more or less a 50% dose reduction in the cumulative chemotherapy compared to a younger patient who gets R-CHOP21. At our institution, we have developed a regimen called split-dose R-CHOP, which basically fractionates R-CHOP21 into two half doses with full-dose rituximab given on day one, and a 50% dose reduction of the CHOP regimen on day one and day 15, so that a 28-day cycle of split-dose R-CHOP gave the same chemo cumulative dose of chemotherapy as R-CHOP21. We designed this study as a way to deliver the same dose intensity to older patients, but by fractionating it, making it more tolerable to a patient population that's at higher risk of the toxicities associated with chemotherapy. In addition, because older patients could benefit from a truncated chemotherapy regimen, we included an interim analysis of patients, where we looked at them using PET-CT and MRD, using a cell-free DNA assay- [inaudible 00:01:33]- ... to look at the depth of response after two months of split-dose R-CHOP. For those patients who are both MRD-negative and, by Deauville criteria, a PET score of one, two, or three, those patients were then offered an abbreviated chemotherapy arm where they would finish after four months of split-dose R-CHOP instead of six months. Here, we are presenting our interim feasibility endpoint, which was based on the end-of-treatment CR rate. We're reporting data on 14 patients who have completed treatment, and our end-of-CR rate with 71%, meeting our interim feasibility endpoint early with 10 of the 14 patients achieving a complete remission. Overall, this regimen was well-tolerated. There were adverse events as described in the data that we've shown, but some of these are to be expected treating an older patient population, but there were no treatment-related deaths directly related to the chemotherapy. The most interesting aspect of this data was, however, that analysis we did using PET-CT and MRD. For six patients, who were both MRD-negative and PET-CT-negative, five of the six went onto the abbreviated arm. Even though they finished this truncated regimen, all of them remained in remission to-date. This shows that there might be power in this early-responding group that have a high in-depth- [inaudible 00:03:03]- ... response of this early interim analysis. We look forward to sharing this data at ASCO, and continuing to enroll patients, but we think that this could become a paradigm on how to treat older patients with DLBCL using novel endpoints, while offering a regimen with the same dose intensity that we offer younger patients to improve efficacy.

Related Videos

Lung Cancer

Narjust Florez, MD, and Filippo Gustavo Dall’Olio, MD, on NSCLC: New Findings on Tumor Fraction, Durvalumab, and Survival

Narjust Florez, MD, of Dana-Farber Cancer Institute, and Filippo Gustavo Dall’Olio, MD, of Institut Gustave Roussy, discuss circulating tumor DNA tumor fraction, and its link to survival in patients with advanced non–small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial. Tumor fraction was positive in 16% of patients randomly assigned to receive durvalumab in the study. This population seems to have a limited benefit from maintenance durvalumab after induction chemotherapy (Abstract 2516).

Skin Cancer
Immunotherapy

Allison Betof Warner, MD, PhD, and Adnan Khattak, PhD, MBBS, on High-Risk Resected Melanoma: Survival Results With mRNA-4157 and Pembrolizumab in KEYNOTE-942

Allison Betof Warner, MD, PhD, of Stanford University Medical Center, and Adnan Khattak, MBBS, FRACP, PhD, of Australia’s Hollywood Private Hospital & Edith Cowan University, discuss the use of the mRNA-4157 vaccine in combination with pembrolizumab as adjuvant therapy for resected high-risk melanoma, which prolonged distant metastasis–free survival compared with pembrolizumab alone. These results provide further evidence that a personalized neoantigen approach is potentially beneficial (Abstract LBA9503).

Kidney Cancer
Immunotherapy

Rana R. McKay, MD, and Brian I. Rini, MD, on Clear Cell RCC: New Data From KEYNOTE-426 on Pembrolizumab Plus Axitinib vs Sunitinib

Rana R. McKay, MD, of the University of California, San Diego, and Brian I. Rini, MD, of Vanderbilt-Ingram Cancer Center, discuss the 5-year follow-up results with the combination of a checkpoint inhibitor plus a VEGFR tyrosine kinase inhibitor as first-line treatment for patients with advanced clear cell renal cell carcinoma (RCC). Pembrolizumab plus axitinib continued to demonstrate improved survival outcomes as well as overall response rate vs sunitinib for patients with previously untreated disease (Abstract LBA4501).

Lymphoma
Immunotherapy

Tycel J. Phillips, MD, and Swetha Kambhampati, MD, on Mantle Cell Lymphoma: Real-World Outcomes With Brexucabtagene Autoleucel

Tycel J. Phillips, MD, and Swetha Kambhampati, MD, both of City of Hope National Medical Center, discuss new findings showing that the real-world effectiveness and safety of brexucabtagene autoleucel were similar to data from the pivotal ZUMA-2 trial in patients with relapsed or refractory mantle cell lymphoma, regardless of prior BTK inhibition, bendamustine, or autologous stem cell transplantation (Abstract 7507).

Lung Cancer

Narjust Florez, MD, and Roy S. Herbst, MD, on NSCLC: Overall Survival Analysis From the ADAURA Trial of Osimertinib

Narjust Florez, MD, of Dana-Farber Cancer Institute, and Roy S. Herbst, MD, PhD, of Yale Cancer Center, discuss new phase III findings on osimertinib, a third-generation, central nervous system EGFR-TKI, which demonstrated an unprecedented overall survival benefit for patients with EGFR-mutated, stage IB–IIIA non–small cell lung cancer after complete tumor resection, with or without adjuvant chemotherapy (Abstract LBA3).

Advertisement

Advertisement




Advertisement